(Q45239344)

11 December 2017

Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study (English)

1 reference

11 December 2017

J A Kanis

1

1 reference

11 December 2017

F Borgström

2

1 reference

11 December 2017

O Johnell

3

1 reference

11 December 2017

A Oden

4

1 reference

11 December 2017

D Sykes

5

1 reference

11 December 2017

B Jönsson

6

1 reference

11 December 2017

language of work or name

English

0 references

publication date

24 July 2004

1 reference

Osteoporosis International

11 December 2017

1 reference

11 December 2017

16

1 reference

11 December 2017

1

1 reference

11 December 2017

15-25

1 reference

https://scigraph.springernature.com/pub.10.1007/s00198-004-1688-0

11 December 2017

0 references

cites work

Mortality after osteoporotic fractures

1 reference

12 December 2020

Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial

1 reference

12 December 2020

A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention

1 reference

12 December 2020

Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis

1 reference

12 December 2020

Mortality after all major types of osteoporotic fracture in men and women: an observational study.

1 reference

12 December 2020

Bone-density measurement

1 reference

12 December 2020

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

12 December 2020

Prevention of coronary heart disease through treatment of infection with Chlamydia pneumoniae? Estimation of possible effectiveness and costs.

1 reference

12 December 2020

Treatment of established osteoporosis: a systematic review and cost-utility analysis.

1 reference

12 December 2020

Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study

1 reference

12 December 2020

A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer

1 reference

12 December 2020

Colles' fracture of the wrist as an indicator of underlying osteoporosis in postmenopausal women: a prospective study of bone mineral density and bone turnover rate

1 reference

12 December 2020

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

1 reference

12 December 2020

Cost-effectiveness of preventing hip fracture in the general female population.

1 reference

12 December 2020

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

1 reference

12 December 2020

The effect of postmenopausal estrogen therapy on bone density in elderly women

1 reference

12 December 2020

The Cost Effectiveness of Hypertension Treatment in Sweden

1 reference

12 December 2020

Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study

1 reference

12 December 2020

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

1 reference

12 December 2020

Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis

1 reference

12 December 2020

Variations in population health status: results from a United Kingdom national questionnaire survey

1 reference

12 December 2020

Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women

1 reference

12 December 2020

Population-based study of survival after osteoporotic fractures

1 reference

12 December 2020

Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group

1 reference

12 December 2020

Increments in Bone Mineral Density of the Lumbar Spine and Hip and Suppression of Bone Turnover Are Maintained after Discontinuation of Alendronate in Postmenopausal Women

1 reference

12 December 2020

Risk of Mortality Following Clinical Fractures

1 reference

12 December 2020

A computer model to analyze the cost-effectiveness of hormone replacement therapy

1 reference

12 December 2020

The risk and burden of vertebral fractures in Sweden

1 reference

12 December 2020

Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group

1 reference

12 December 2020

The cost of treating osteoporotic fractures in the United Kingdom female population.

1 reference

12 December 2020

Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden.

1 reference

12 December 2020

Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group

1 reference

12 December 2020

Long-term risk of osteoporotic fracture in Malmö.

1 reference

12 December 2020

Breast cancer and hormone-replacement therapy in the Million Women Study

1 reference

12 December 2020

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

12 December 2020

Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study

1 reference

12 December 2020

Quantitative ultrasound and bone mineral density are equally strongly associated with risk factors for osteoporosis

1 reference

12 December 2020

A systematic review of health state utility values for osteoporosis-related conditions

1 reference

12 December 2020

NICE: faster access to modern treatments? Analysis of guidance on health technologies

1 reference

12 December 2020

Definition, interpretation and calculation of cost-effectiveness acceptability curves.

1 reference

12 December 2020

Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS).

1 reference

12 December 2020

Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study

1 reference

12 December 2020

Bone Mass and the Risk of Breast Cancer among Postmenopausal Women

1 reference

12 December 2020

Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women

1 reference

12 December 2020

Association between vertebral fracture and increased mortality in osteoporotic patients

1 reference

12 December 2020

Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis

1 reference

12 December 2020

Intervention thresholds for osteoporosis

1 reference

12 December 2020

Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies

1 reference

12 December 2020

Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study

1 reference

12 December 2020

Hormone replacement therapy in a risk-benefit perspective.

1 reference

12 December 2020

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

12 December 2020

Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures

1 reference

12 December 2020

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

1 reference

12 December 2020

10.1007/S00198-004-1688-0

Identifiers

DOI

1 reference

Dimensions Publication ID

11 December 2017

0 references

1 reference